Hormone may help fight obesity and reduce cholesterol

September 3, 2013

Research has shown that giving obese rodents a recently identified circulating protein called fibroblast growth factor 21 (FGF21) helps improve their metabolism. Now investigators reporting in the Cell Press journal Cell Metabolism reveal that a variant of FGF21 has similar effects in obese people with type 2 diabetes.

"Our findings suggest that FGF21 has the ability to favorably affect body weight and to partially normalize abnormal lipid levels in patients with diabetes. These are substantial issues and unmet medical needs for patients with obesity and ," says senior author Dr. David Moller, vice president of endocrine and cardiovascular research at Eli Lilly and Company.

Lilly scientists initially identified FGF21 as a novel target for its potential in treating metabolic disorders. Dr. Moller and his colleagues studied the effects of LY2405319 (LY), a variant of FGF21, in a randomized, placebo-controlled, double-blind proof-of-concept trial in 46 patients with obesity and type 2 diabetes. LY treatment led to decreases in LDL cholesterol and triglycerides, increases in HDL cholesterol, and decreases in atherosclerosis-causing lipoproteins.

LY also reduced body weight and fasting insulin, and it increased adiponectin, a hormone produced by that may augment insulin's effects. While there was only a slight lowering of in patients treated with LY, the study's results indicate that FGF21 is active in humans and suggest that FGF21-based therapies may be effective for treating metabolic disorders.

"We are encouraged by the potential of FGF21 to produce multiple metabolic effects in people with diabetes and are evaluating further concepts for FGF21-based therapies," says Dr. Moller. He notes that most people with diabetes have other risk factors related to metabolic syndrome, including , abdominal obesity, elevated triglycerides, low HDL cholesterol levels, and hypertension. No currently available treatment is able to address more than one of these conditions. "Thus, combination therapy is usually prescribed and often leads to tolerability issues, poor patient compliance, and suboptimal outcomes, all of which provide an incentive to continue the search for new therapeutic approaches," Dr. Moller explains.

Explore further: Antibody injection promising for diabetes and obesity

More information: Cell Metabolism, Gaich et al.: "The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes." dx.doi.org/10.1016/j.cmet.2013.08.005

Related Stories

Antibody injection promising for diabetes and obesity

December 16, 2011

(Medical Xpress) -- Researchers at Genetech Inc. in South San Francisco, California, led by molecular biologist Junichiro Sonoda, have discovered that a single injection of antibodies into obese diabetic mice provided a marked ...

Recommended for you

Functional human liver cells grown in the lab

November 26, 2015

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

IJ Coleman
not rated yet Sep 04, 2013
I much prefer using the new options under my insurance: http://navixmarke...amacare/

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.